bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 4 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma
Authors: Radon Tomasz P. , Massat Nathalie J. , Jones Richard , Alrawashdeh Wasfi , Dumartin Laurent , Ennis Darren , Duffy Stephen W. , Kocher Hemant M. , Pereira Stephen P. , Guarner (posthumous) Luisa , Murta-Nascimento Cristiane , Real Francisco X. , Malats Núria , Neoptolemos John , Costello Eithne , Greenhalf William , Lemoine Nick R. , Crnogorac-Jurcevic Tatjana
Published: April 2023

Exploratory comparison of plasma CA19.9 and the urine biomarker panel in discriminating early pancreatic adenocarcinoma from chronic pancreatitis patients. A, ROC curves of the biomarker panel with corresponding plasma CA19.9 alone and in combination comparing CP urine (n=50), and urines from PDAC stages I-II (n=71) and, I-IIA (n=16) (B). C, Summary table. AUC: area under the curve, SN: sensitivity, SP: specificity with 95% Confidence Interval (CI). SN and SP in the validation set were derived for optimal cutpoint determined in the training dataset.
Supplementary Figure 2 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma
Authors: Radon Tomasz P. , Massat Nathalie J. , Jones Richard , Alrawashdeh Wasfi , Dumartin Laurent , Ennis Darren , Duffy Stephen W. , Kocher Hemant M. , Pereira Stephen P. , Guarner (posthumous) Luisa , Murta-Nascimento Cristiane , Real Francisco X. , Malats Núria , Neoptolemos John , Costello Eithne , Greenhalf William , Lemoine Nick R. , Crnogorac-Jurcevic Tatjana
Published: April 2023

Correlation of the three urinary biomarkers and plasma CA19.9 (CA19.9p). A, Correlation plots (Navy blue: Healthy; Turquoise: chronic pancreatitis (CP); Purple: pancreatic adenocarcinoma (PDAC). B, Pearson correlation coefficients and corresponding significance (NS: non-significant, *: p<0.05, **: p<0.01, ***: p<0.001).
Supplementary Table 1 from Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors
Authors: Endo Makoto , Yamamoto Hidetaka , Setsu Nokitaka , Kohashi Kenichi , Takahashi Yusuke , Ishii Takeaki , Iida Kei-ichiro , Matsumoto Yoshihiro , Hakozaki Michiyuki , Aoki Mikiko , Iwasaki Hiroshi , Dobashi Yoh , Nishiyama Kenichi , Iwamoto Yukihide , Oda Yoshinao
Published: April 2023

XLSX file - 9K, A comparison of p-Akt, p-mTOR, p-S6RP, p-p70S6K and p-4E-BP1 expression results in all specimens
Supplementary Figure 3 from SIRT6 Overexpression Potentiates Apoptosis Evasion in Hepatocellular Carcinoma via BCL2-Associated X Protein–Dependent Apoptotic Pathway
Authors: Ran Long-Kuan , Chen Yong , Zhang Zhen-Zhen , Tao Na-Na , Ren Ji-Hua , Zhou Li , Tang Hua , Chen Xiang , Chen Ke , Li Wan-Yu , Huang Ai-Long , Chen Juan
Published: April 2023

SIRT6 overexpression promotes the proliferation of the immortalized liver cell line MIHA. (A) Trypan blue exclusion assay with MIHA cells transduced with lentiviruses expressing plenti6-SIRT6 or the corresponding empty vector. Cell numbers were counted at the indicated number of days. *, p<0.01. (B) Soft agar assay. MIHA cells transduced with lentiviruses expressing plenti6-SIRT6 or the corresponding empty vector were grown in soft agar for 3 weeks. The quantification of colonies was performed by counting visible colonies in each well and expressing then as a percentage relative to control cells. *, p<0.01. (C) EdU incorporation assay of MIHA cells overexpressing SIRT6 or vector. *, p<0.01. (D) SIRT6 overexpression resulted in cell resistance to doxorubicin. Cells overexpressing SIRT6 or vector were treated with doxorubicin (0.75μM ) for 48 h and subjected to flow cytometry with Annexin V/PI. *, p<0.01.
Supplementary Figure 2 from Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma
Authors: Veal Gareth J. , Errington Julie , Rowbotham Sophie E. , Illingworth Nicola A. , Malik Ghada , Cole Michael , Daly Ann K. , Pearson Andrew D.J. , Boddy Alan V.
Published: April 2023

PDF file - 43K, Relationship between 13-cisRA AUC0-6h and 13-cisRA Cmax determined from pharmacokinetic profiles obtained following protocol-based 13-cisRA dosing (n=103)
Supplementary Figure 2 from Prospero Homeobox 1 Promotes Epithelial–Mesenchymal Transition in Colon Cancer Cells by Inhibiting E-cadherin via miR-9
Authors: Lu Mei-Hsuan , Huang Chao-Cheng , Pan Mei-Ren , Chen Hong-Hwa , Hung Wen-Chun
Published: April 2023

PDF file - 88K, PROX1 induces an EMT change
Supplementary Figure 1 from Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Authors: Kim Edward J. , Sahai Vaibhav , Abel Ethan V. , Griffith Kent A. , Greenson Joel K. , Takebe Naoko , Khan Gazala N. , Blau John L. , Craig Ronald , Balis Ulysses G. , Zalupski Mark M. , Simeone Diane M.
Published: April 2023

Supplementary Figure 1. Median overall survival correlated with change in CA 19-9 (>50% decrease, versus {less than or equal to}50% decrease, or primary increase) compared to baseline.
Supplementary Table 2 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Authors: Sabbatini Paul , Tsuji Takemasa , Ferran Luis , Ritter Erika , Sedrak Christine , Tuballes Kevin , Jungbluth Achim A. , Ritter Gerd , Aghajanian Carol , Bell-McGuinn Katherine , Hensley Martee L. , Konner Jason , Tew William , Spriggs David R. , Hoffman Eric W. , Venhaus Ralph , Pan Linda , Salazar Andres M. , Diefenbach Catherine Magid , Old Lloyd J. , Gnjatic Sacha
Published: April 2023

PDF file - 70K, Incidence of treatment-related adverse events by maximum grade
Supplementary Table 1 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Authors: Sabbatini Paul , Tsuji Takemasa , Ferran Luis , Ritter Erika , Sedrak Christine , Tuballes Kevin , Jungbluth Achim A. , Ritter Gerd , Aghajanian Carol , Bell-McGuinn Katherine , Hensley Martee L. , Konner Jason , Tew William , Spriggs David R. , Hoffman Eric W. , Venhaus Ralph , Pan Linda , Salazar Andres M. , Diefenbach Catherine Magid , Old Lloyd J. , Gnjatic Sacha
Published: April 2023

PDF file - 65K, Immunohistochemical analysis of NY-ESO-1 expression (mAb E978) in tumor tissue and vaccine regimen
Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Ma Cynthia X. , Sanchez Cesar , Gao Feng , Crowder Robert , Naughton Michael , Pluard Timothy , Creekmore Allison , Guo Zhanfang , Hoog Jeremy , Lockhart A. Craig , Doyle Austin , Erlichman Charles , Ellis Matthew J.
Published: April 2023

This supplementary figure shows the appearance of the rash and the histology of the skin biopsy. This needs to be a colored figure.
Supplementary Figure Legend from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Authors: Sabbatini Paul , Tsuji Takemasa , Ferran Luis , Ritter Erika , Sedrak Christine , Tuballes Kevin , Jungbluth Achim A. , Ritter Gerd , Aghajanian Carol , Bell-McGuinn Katherine , Hensley Martee L. , Konner Jason , Tew William , Spriggs David R. , Hoffman Eric W. , Venhaus Ralph , Pan Linda , Salazar Andres M. , Diefenbach Catherine Magid , Old Lloyd J. , Gnjatic Sacha
Published: April 2023

PDF file - 68K
Supplementary Table 2 from Calreticulin Promotes Migration and Invasion of Esophageal Cancer Cells by Upregulating Neuropilin-1 Expression via STAT5A
Authors: Shi Feng , Shang Li , Pan Bei-Qing , Wang Xiao-Min , Jiang Yan-Yi , Hao Jia-Jie , Zhang Yu , Cai Yan , Xu Xin , Zhan Qi-Min , Wang Ming-Rong
Published: April 2023

Supplementary Table 2. Relationship between NRP1/CRT co-expression and lymph node metastasis in 216 ESCC patients
Supplementary Figure 3 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Authors: Sabbatini Paul , Tsuji Takemasa , Ferran Luis , Ritter Erika , Sedrak Christine , Tuballes Kevin , Jungbluth Achim A. , Ritter Gerd , Aghajanian Carol , Bell-McGuinn Katherine , Hensley Martee L. , Konner Jason , Tew William , Spriggs David R. , Hoffman Eric W. , Venhaus Ralph , Pan Linda , Salazar Andres M. , Diefenbach Catherine Magid , Old Lloyd J. , Gnjatic Sacha
Published: April 2023

PDF file - 1810K, Detection of NY-ESO-1-specific CD4+ T cells by intracellular cytokine staining. CD4+ T cells were stimulated once with T-cell depleted PBMC pulsed with NY-ESO-1 assay OLP and after 22-23 day culture, NY-ESO-1-specific IFN-γ and IL-5 production was evaluated by intracellular cytokine staining. Peptide-pulsed or unpulsed autologous EBV-B cells pulsed or unpulsed with 20-mer NY-ESO-1 peptides covering areas indicated were used as target cells. Responses shown at week 16 after vaccination in two patients (M09 and M19) representative of Cohort 2 and 3, respectively.
Supplementary Figure 2 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Authors: Sabbatini Paul , Tsuji Takemasa , Ferran Luis , Ritter Erika , Sedrak Christine , Tuballes Kevin , Jungbluth Achim A. , Ritter Gerd , Aghajanian Carol , Bell-McGuinn Katherine , Hensley Martee L. , Konner Jason , Tew William , Spriggs David R. , Hoffman Eric W. , Venhaus Ralph , Pan Linda , Salazar Andres M. , Diefenbach Catherine Magid , Old Lloyd J. , Gnjatic Sacha
Published: April 2023

PDF file - 196K, Humoral immune responses to NY-ESO-1 protein and peptides in individual patients throughout vaccination with NY-ESO-1 OLP. A) Reciprocal titers of plasma IgG antibodies were measured throughout vaccination by ELISA against NY-ESO-1 recombinant protein. Each patient was tested for all available time points, from prestudy (pre) up to week (w) 16. B) IgG plasma antibody responses were analyzed using 20-mer OLP in ELISA from samples at the time points where maximal titers had been achieved against NY-ESO-1 protein following vaccination. Peaks represent titers against 20-mer individual peptides centered around amino-acids from NY-ESO-1 shown along the X-axis. Reciprocal titers were considered significant if > 100. Assays representative of at least 2 repeats.
Supplemental Figure S1 and Figure S2. from A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
Authors: Messersmith Wells A. , Shapiro Geoffrey I. , Cleary James M. , Jimeno Antonio , Dasari Arvind , Huang Bo , Shaik M. Naveed , Cesari Rossano , Zheng Xianxian , Reynolds Jennifer M. , English Patricia A. , McLachlan Karen R. , Kern Kenneth A. , LoRusso Patricia M.
Published: April 2023

Supplemental Figure S1 and Figure S2. Figure S1: Pharmacokinetic profiles of PF-03084014 following administration to patients with solid malignancies. Figure S2. Downregulation of Hes4 gene expression following treatment with PF-03084014 in patients with solid malignancies.
Supplementary figure 5 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy
Authors: Feng Liang , Yao Hang-Ping , Wang Wei , Zhou Yong-Qing , Zhou Jianwei , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

Supplementary figure 5. Correlations of Zt/g4-DM1 Concentrations with Tumor Growth in vivo
Supplementary Table 2 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy
Authors: Feng Liang , Yao Hang-Ping , Wang Wei , Zhou Yong-Qing , Zhou Jianwei , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

Supplementary Table 2. Time-Dependent Stability of Zt/g4-DM1 at 37{degree sign}C
Related Article from Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer?
Authors: Crystal Adam S. , Shaw Alice T.
Published: April 2023

Related Article from Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer?
Supplementary Methods from Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
Authors: Jahangiri Arman , De Lay Michael , Miller Liane M. , Carbonell W. Shawn , Hu Yu-Long , Lu Kan , Tom Maxwell W. , Paquette Jesse , Tokuyasu Taku A. , Tsao Sean , Marshall Roxanne , Perry Arie , Bjorgan Kirsten M. , Chaumeil Myriam M. , Ronen Sabrina M. , Bergers Gabriele , Aghi Manish K.
Published: April 2023

PDF file - 120K
Supplementary Figure 4 from Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity
Authors: Khiati Salim , Dalla Rosa Ilaria , Sourbier Carole , Ma Xuefei , Rao V. Ashutosh , Neckers Leonard M. , Zhang Hongliang , Pommier Yves
Published: April 2023

PDF file - 108KB, Distribution of the mutations along the Top1mt polypeptide. Red: Deleterious missense variants. Blue: Essential amino acids (aa) for Top1mt activity. Green: High frequent missense variants.
Supplementary Data from First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
Authors: Blagden Sarah , Olmin Aurelius , Josephs Debra , Stavraka Chara , Zivi Andrea , Pinato David J. , Anthoney Alan , Decordova Shaun , Swales Karen , Riisnaes Ruth , Pope Lorna , Noguchi Kohei , Shiokawa Rie , Inatani Michiyasu , Prince Jenny , Jones Keith , Twelves Chris , Spicer James , Banerji Udai
Published: April 2023

Supplementary Data. Inclusion and exclusion criteria
Figure Legend from The Novel Organic Arsenical Darinaparsin Induces MAPK-Mediated and SHP1-Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models
Authors: Ravi Dashnamoorthy , Bhalla Savita , Gartenhaus Ronald B. , Crombie Jennifer , Kandela Irawati , Sharma Jaya , Mazar Andrew , Evens Andrew M.
Published: April 2023

Figure Legend. Legend for supplemental figure S1
Supplementary Figure 1 from Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Authors: Iglesia Michael D. , Vincent Benjamin G. , Parker Joel S. , Hoadley Katherine A. , Carey Lisa A. , Perou Charles M. , Serody Jonathan S.
Published: April 2023

PDF file - 30K, Signatures of lymphocyte infiltration in breast tumors are highly correlated in A an mRNA-seq expression data set of 728 breast tumors and 91 normal breast samples B an mRNA-seq expression data set of 266 ovarian tumors.
Supplementary Table S2 from Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome
Authors: Deckers Ivette A.G. , Schouten Leo J. , Van Neste Leander , van Vlodrop Iris J.H. , Soetekouw Patricia M.M.B. , Baldewijns Marcella M.L.L. , Jeschke Jana , Ahuja Nita , Herman James G. , van den Brandt Piet A. , van Engeland Manon
Published: April 2023

Genomic information of the CDO1 probes selected from The Cancer Genome Atlas (TCGA) data.
Supplementary Figures 1 - 3 from Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Authors: Tamada Koji , Geng Degui , Sakoda Yukimi , Bansal Navneeta , Srivastava Ratika , Li Zhaoyang , Davila Eduardo
Published: April 2023

PDF file - 46K, Supplemental Figure 1. A capacity of tumor-infiltrating anti-FITC CAR T cells to produce cytokines/chemokines in response to FITC stimulation; Supplemental Figure 2. Functional role of human CD3ζ/CD28/4-1BB signaling motifs in mouse CAR T cell activation; Supplemental Figure 3. Development of anti-FITC Ab responses in the mice injected with FITC-conjugated Ab
Data Supplement from Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors
Authors: van der Biessen Diane A.J. , Burger Herman , de Bruijn Peter , Lamers Cor H.J. , Naus Nicole , Loferer Hannes , Wiemer Erik A.C. , Mathijssen Ron H.J. , de Jonge Maja J.A.
Published: April 2023

Supplementary Figure S1: Chemical structure of RGB-286638
Data Supplement from Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors
Authors: van der Biessen Diane A.J. , Burger Herman , de Bruijn Peter , Lamers Cor H.J. , Naus Nicole , Loferer Hannes , Wiemer Erik A.C. , Mathijssen Ron H.J. , de Jonge Maja J.A.
Published: April 2023

Supplementary Figure S2: Relationship between area under the curves (AUC) and the administered dose on day 1 of drug intake.
Supplementary Figure S4 from The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
Authors: Krepler Clemens , Chunduru Srinivas K. , Halloran Molly B. , He Xu , Xiao Min , Vultur Adina , Villanueva Jessie , Mitsuuchi Yasuhiro , Neiman Eric M. , Benetatos Christopher , Nathanson Katherine L. , Amaravadi Ravi K. , Pehamberger Hubert , McKinlay Mark , Herlyn Meenhard
Published: April 2023

PDF file - 79 KB, Levels of TNF-� in cell culture supernatant.
Supplementary Figure S1 from The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
Authors: Krepler Clemens , Chunduru Srinivas K. , Halloran Molly B. , He Xu , Xiao Min , Vultur Adina , Villanueva Jessie , Mitsuuchi Yasuhiro , Neiman Eric M. , Benetatos Christopher , Nathanson Katherine L. , Amaravadi Ravi K. , Pehamberger Hubert , McKinlay Mark , Herlyn Meenhard
Published: April 2023

PDF file - 121 KB, Seventeen human melanoma cell lines representing major mutational subgroups of cutaneous melanoma were treated with TNF-� at concentrations up to 50ng/ml.
Supplementary Figure 4 from PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate–Sensitive or –Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo
Authors: Dasmahapatra Girija , Patel Hiral , Nguyen Tri , Attkisson Elisa , Grant Steven
Published: April 2023

PDF file - 104K, Co-treatment with BI2536 or PLK-1 knockdown by shRNA and vorinostat arrests cells in G2M phase. (A) K562 cells were treated with 5.0 nM BI2536 � 1.5 �M vorinostat. (B-C) K562 cells transiently transfected with scramble sequence or shPLK-1 and treated with vorinostat (1.5 �M) for 24 hr. Following drug exposure, cells were collected, fixed in ice cold methanol at a ratio of 1 mL PBS to 4 mL ice cold ethanol, and analyzed by flow cytometry using Modfit software as described in Methods. Duplicate experiments yielded equivalent results.
Supplementary Figure 3 from PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate–Sensitive or –Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo
Authors: Dasmahapatra Girija , Patel Hiral , Nguyen Tri , Attkisson Elisa , Grant Steven
Published: April 2023

PDF file - 82K, Knock-down of histone 1.2 protects K562 cells from the lethal effects of combined BI2536 and vorinostat treatment. (A) K562 cells were transiently transfected with scramble sequence or shH1.2 as described in Methods and treated with BI2536 (4.0 nM) and vorinostat (1.25 �M) for 48 hr. Cell death was monitored by 7AAD staining and flow cytometry. Inset: Western blots showing expression of histone 1.2 expression in empty vector control and knockdown cells. (B) K562 cells were transiently transfected with scramble sequence or shH1.2 as described in Methods and treated with BI and vorinostat as (A) above for 24 hr, after which expression of the indicated proteins was monitored by western blotting.
Supplementary Figure S2 from G Protein–Coupled Estrogen Receptor Is Apoptotic and Correlates with Increased Distant Disease-Free Survival of Estrogen Receptor–Positive Breast Cancer Patients
Authors: Broselid Stefan , Cheng Benxu , Sjöström Martin , Lövgren Kristina , Klug-De Santiago Heather L.P. , Belting Mattias , Jirström Karin , Malmström Per , Olde Björn , Bendahl Pär-Ola , Hartman Linda , Fernö Mårten , Leeb-Lundberg L.M. Fredrik
Published: April 2023

Pro-apoptotic signaling by increasing concentrations of G1 and 4OHT in T47D cells. Cell lysates were immunoblotted for cytochrome C and cleaved PARP. β-Actin serves as a loading control.
Supplementary Figure S1 from G Protein–Coupled Estrogen Receptor Is Apoptotic and Correlates with Increased Distant Disease-Free Survival of Estrogen Receptor–Positive Breast Cancer Patients
Authors: Broselid Stefan , Cheng Benxu , Sjöström Martin , Lövgren Kristina , Klug-De Santiago Heather L.P. , Belting Mattias , Jirström Karin , Malmström Per , Olde Björn , Bendahl Pär-Ola , Hartman Linda , Fernö Mårten , Leeb-Lundberg L.M. Fredrik
Published: April 2023

Confocal immunofluorescence microscopy of GPER1 in HEK transiently transfected with FGPER1 and treated without (-EPX) and with 50 nM EPX for 24 hr (+EPX). FGPER1 is shown in green and endogenous cytokeratin 8 is shown in red.
Table A2 from Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review
Authors: Li Xiao , You Ran , Wang Xinwei , Liu Congxin , Xu Zicheng , Zhou Jin , Yu Bin , Xu Ting , Cai Hongzhou , Zou Qing
Published: April 2023

Table A2 BPM and BC risk in BRCA1/2 mutation carriers
Table A1 from Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review
Authors: Li Xiao , You Ran , Wang Xinwei , Liu Congxin , Xu Zicheng , Zhou Jin , Yu Bin , Xu Ting , Cai Hongzhou , Zou Qing
Published: April 2023

Table A1 PBSO and BC risk in BRCA1/2 mutation carriers
Supplementary Table S1, Table S2 and Figure legends from miR-204-5p Inhibits Proliferation and Invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating RAB22A
Authors: Yin Yuan , Zhang Binbin , Wang Weili , Fei Bojian , Quan Chao , Zhang Jiwei , Song Mingxu , Bian Zehua , Wang Qifeng , Ni Shujuan , Hu Yaling , Mao Yong , Zhou Leyuan , Wang Yugang , Yu Jian , Du Xiang , Hua Dong , Huang Zhaohui
Published: April 2023

Supplementary Table S1. Patients' information Supplementary Table S2. Primer sequences Supplementary Figure Legends
Figure-S7 from AMACR Amplification in Myxofibrosarcomas: A Mechanism of Overexpression That Promotes Cell Proliferation with Therapeutic Relevance
Authors: Li Chien-Feng , Fang Fu-Min , Lan Jui , Wang Jun-Wen , Kung Hsing-Jien , Chen Li-Tzong , Chen Tzu-Ju , Li Shau-Hsuan , Wang Yu-Hui , Tai Hui-Chun , Yu Shih-Chen , Huang Hsuan-Ying
Published: April 2023

Figure-S7 Ebselen oxide (EO) at 40 μM significantly increases the subG0-1 cell populations in myxofibrosarcoma cell lines. In the flow cytometric analysis for both NMFH-1 (upper) and NMFH-2 (lower) cell lines, the significantly increased cell percentage in the subG0-1 phase is induced by EO treatment at 40 μM and especially prominent in the NMFH-1. However, neither vehicle controls nor EO treatment at 20 μM shows such an apoptosis-inducing effect.
Supplementary Figure Legend from Abiraterone Inhibits 3β-Hydroxysteroid Dehydrogenase: A Rationale for Increasing Drug Exposure in Castration-Resistant Prostate Cancer
Authors: Li Rui , Evaul Kristen , Sharma Kamalesh K. , Chang Kai-Hsiung , Yoshimoto Jennifer , Liu Jiayan , Auchus Richard J. , Sharifi Nima
Published: April 2023

PDF file - 61K
Figure-S1 from AMACR Amplification in Myxofibrosarcomas: A Mechanism of Overexpression That Promotes Cell Proliferation with Therapeutic Relevance
Authors: Li Chien-Feng , Fang Fu-Min , Lan Jui , Wang Jun-Wen , Kung Hsing-Jien , Chen Li-Tzong , Chen Tzu-Ju , Li Shau-Hsuan , Wang Yu-Hui , Tai Hui-Chun , Yu Shih-Chen , Huang Hsuan-Ying
Published: April 2023

Figure-S1 The induction of cell cycle arrests in the different phases by shAMACR in NMFH-1 and NMFH-2 cell lines. In representative flow cytometric experiments, two stable clones each of AMACR-knockdown NMFH-1 (upper) and NMFH-2 (lower) cells display cell cycle arrests, occurring primarily in the G1 phase and G2/M phase, respectively.
Supplementary Figure 1 from Abiraterone Inhibits 3β-Hydroxysteroid Dehydrogenase: A Rationale for Increasing Drug Exposure in Castration-Resistant Prostate Cancer
Authors: Li Rui , Evaul Kristen , Sharma Kamalesh K. , Chang Kai-Hsiung , Yoshimoto Jennifer , Liu Jiayan , Auchus Richard J. , Sharifi Nima
Published: April 2023

PDF file - 237K, Structures and synthetic scheme for abi and delta4-abi
Suppl Table S5 from RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma
Authors: Mi Shijun , Lin Mingyan , Brouwer-Visser Jurriaan , Heim Jennifer , Smotkin David , Hebert Tiffany , Gunter Marc J. , Goldberg Gary L. , Zheng Deyou , Huang Gloria S.
Published: April 2023

Table S5. YM155 Sensitivity in Primary CS cell lines and CS99 cells.
Supplementary Figure S4 from Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Authors: Sharkey Robert M. , McBride William J. , Cardillo Thomas M. , Govindan Serengulam V. , Wang Yang , Rossi Edmund A. , Chang Chien-Hsing , Goldenberg David M.
Published: April 2023

Figure S4. Concentrations of products in the liver of mice (N = 3) given irinotecan or IMMU-132 determined in 2 separate studies.
Suppl Table S1 from RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma
Authors: Mi Shijun , Lin Mingyan , Brouwer-Visser Jurriaan , Heim Jennifer , Smotkin David , Hebert Tiffany , Gunter Marc J. , Goldberg Gary L. , Zheng Deyou , Huang Gloria S.
Published: April 2023

Table S1. RNA-seq Data Summary.
Supplemental Tables 1, 2, 3 from Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas
Authors: Chong Elise A. , Ahmadi Tahamtan , Aqui Nicole A. , Svoboda Jakub , Nasta Sunita D. , Mato Anthony R. , Walsh Kristy M. , Schuster Stephen J.
Published: April 2023

Supplemental Tables 1, 2, 3. Supplemental Table 1. Patient characteristics and outcomes for each cohort; Supplemental Table 2. Dose reductions and interruptions; Supplemental Table 3. PFS for rituximab resistance-defining regimen and lenalidomide-rituximab
Supplementary Figure S1 from Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Authors: Sharkey Robert M. , McBride William J. , Cardillo Thomas M. , Govindan Serengulam V. , Wang Yang , Rossi Edmund A. , Chang Chien-Hsing , Goldenberg David M.
Published: April 2023

Evaluation of the procedure used to quantitate the constitutive products derived from irinotecan or IMMU-132.
Data Supplement from Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
Authors: Haluska Paul , Menefee Michael , Plimack Elizabeth R. , Rosenberg Jonathan , Northfelt Donald , LaVallee Theresa , Shi Li , Yu Xiang-Qing , Burke Patricia , Huang Jaiqi , Viner Jaye , McDevitt Jennifer , LoRusso Patricia
Published: April 2023

Figure S1. Top: mRNA differential expression of individual proliferation genes (AURKA, CCNB1, MKI67, and MYBL2) and cancer invasion genes (CTSL2 and MMP11) and the bladder cancer marker, UPK3A, in biopsy samples (from patients with bladder cancer at pretreatment and after treatment at 5 mg/kg and 15 mg/kg. Bottom: Composite differential expression score from pretreatment and post-treatment tissues of proliferation, invasion, and bladder cancer markers in cohorts 5 mg/kg and 15 mg/kg.
Supplementary Figure 4 from Ectopic Expression of Cancer–Testis Antigens in Cutaneous T-cell Lymphoma Patients
Authors: Litvinov Ivan V. , Cordeiro Brendan , Huang Yuanshen , Zargham Hanieh , Pehr Kevin , Doré Marc-André , Gilbert Martin , Zhou Youwen , Kupper Thomas S. , Sasseville Denis
Published: April 2023

PDF file - 2210KB, Effect of HDAC inhibitors on mRNA expression of CT genes in Hut78 cells.
Supplementary Figure 3 from Ectopic Expression of Cancer–Testis Antigens in Cutaneous T-cell Lymphoma Patients
Authors: Litvinov Ivan V. , Cordeiro Brendan , Huang Yuanshen , Zargham Hanieh , Pehr Kevin , Doré Marc-André , Gilbert Martin , Zhou Youwen , Kupper Thomas S. , Sasseville Denis
Published: April 2023

PDF file - 211KB, T cell stimulation with P+I does not result in a significant mRNA upregulation of CT genes across a panel of CTCL patient-derived cell lines.
Supplementary Figure S1 and S3 from Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
Authors: Somlo George , Atzori Francesco , Strauss Lewis C. , Geese William J. , Specht Jennifer M. , Gradishar William J. , Rybicki Alissa , Sy Oumar , Vahdat Linda T. , Cortes Javier
Published: April 2023

PDF file - 212 KB, Figure S1A. Proportion of cell growth inhibition with the combination of dasatinib and 5- fluorouracil (5FU) in KPL4 breast cancer carcinoma cells in vitro Figure S1B. Proportion of cell growth inhibition with the combination of Dasatinib and 5- FU in HCC70 breast carcinoma cells in vitro Figure S3A. VEGFA changes by patients over baseline who were treated with Dasatinib and 5-FU (current study: CA18004; NCT00452673) Figure S3B. VEGFR2 changes by patients over baseline who were treated with Dasatinib and 5-FU (current study: CA18004; NCT00452673) Figure S3C. Collagen IV (Col-IV ) changes by patients over baseline who were treated with Dasatinib and 5-FU (current study: CA18004; NCT00452673) Figure S3D. VEGFR2 changes in value by patients over baseline (prior single dasatinib studies: CA180059 / NCT00371254 and CA180088/NCT00371345) Figure S3E. Collagen IV (Col-IV ) changes in value by patients over baseline (prior single dasatinib studies: CA180059 / NCT00371254 and CA180088/NCT00371345) Figure S3F. VEGFR2 changes in percentage over baseline (prior single dasatinib studies: CA180059 / NCT00371254 and CA180088/NCT00371345) Figure S3G. Collagen IV (Col-IV ) changes in percentage over baseline (prior single dasatinib studies: CA180059 / NCT00371254 and CA180088/NCT00371345)
Supplementary Figure 2 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Authors: Pal Sumanta , Azad Arun , Bhatia Shailender , Drabkin Harry , Costello Brian , Sarantopoulos John , Kanesvaran Ravindran , Lauer Richard , Starodub Alexander , Hauke Ralph , Sweeney Christopher J. , Hahn Noah M. , Sonpavde Guru , Richey Stephen , Breen Timothy , Kremmidiotis Gabriel , Leske Annabell , Doolin Elizabeth , Bibby David C. , Simpson Jeremy , Iglesias Jose , Hutson Thomas
Published: April 2023

Supplementary Figure 2. CONSORT diagram reflecting patients that received monotherapy with BNC105P after progression on everolimus monotherapy.
Supplementary Figure 1 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Authors: Pal Sumanta , Azad Arun , Bhatia Shailender , Drabkin Harry , Costello Brian , Sarantopoulos John , Kanesvaran Ravindran , Lauer Richard , Starodub Alexander , Hauke Ralph , Sweeney Christopher J. , Hahn Noah M. , Sonpavde Guru , Richey Stephen , Breen Timothy , Kremmidiotis Gabriel , Leske Annabell , Doolin Elizabeth , Bibby David C. , Simpson Jeremy , Iglesias Jose , Hutson Thomas
Published: April 2023

Supplementary Figure 1. PFS in patients receiving BNC105P monotherapy after crossover.
Supplementary Table 2 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
Authors: Filipazzi Paola , Pilla Lorenzo , Mariani Luigi , Patuzzo Roberto , Castelli Chiara , Camisaschi Chiara , Maurichi Andrea , Cova Agata , Rigamonti Gianluigi , Giardino Felicetta , Di Florio Annabella , Asioli Marco , Frati Paola , Sovena Gloria , Squarcina Paola , Maio Michele , Danielli Riccardo , Chiarion-Sileni Vanna , Villa Antonello , Lombardo Claudia , Tragni Gabrina , Santinami Mario , Parmiani Giorgio , Rivoltini Licia
Published: April 2023

PDF file - 56K, Number of IFNγ-forming spots/2 � 105 CD8+ T cells in APL-vaccinated patients
Supplementary Figure 4 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
Authors: Filipazzi Paola , Pilla Lorenzo , Mariani Luigi , Patuzzo Roberto , Castelli Chiara , Camisaschi Chiara , Maurichi Andrea , Cova Agata , Rigamonti Gianluigi , Giardino Felicetta , Di Florio Annabella , Asioli Marco , Frati Paola , Sovena Gloria , Squarcina Paola , Maio Michele , Danielli Riccardo , Chiarion-Sileni Vanna , Villa Antonello , Lombardo Claudia , Tragni Gabrina , Santinami Mario , Parmiani Giorgio , Rivoltini Licia
Published: April 2023

PDF file - 100K, Assessment of peptide-specific recognition by in vitro short-term peptide sensitization assay (IVS)
Data Supplement from Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR–Based Platform
Authors: Guo Wei , Yang Xin-Rong , Sun Yun-Fan , Shen Min-Na , Ma Xiao-Lu , Wu Jiong , Zhang Chun-Yan , Zhou Yan , Xu Yang , Hu Bo , Zhang Xin , Zhou Jian , Fan Jia
Published: April 2023

Supplementary Figure S1. Typical images of spiked Hep3B cells after negative enrichment for CTCs.
Data Supplement from Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR–Based Platform
Authors: Guo Wei , Yang Xin-Rong , Sun Yun-Fan , Shen Min-Na , Ma Xiao-Lu , Wu Jiong , Zhang Chun-Yan , Zhou Yan , Xu Yang , Hu Bo , Zhang Xin , Zhou Jian , Fan Jia
Published: April 2023

Supplementary Figure S2. Representative amplification curves of the intra-run comparison experiments.
Supplementary Table 3 from Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis
Authors: Dal Molin Marco , Zhang Ming , de Wilde Roeland F. , Ottenhof Niki A. , Rezaee Neda , Wolfgang Christopher L. , Blackford Amanda , Vogelstein Bert , Kinzler Kenneth W. , Papadopoulos Nickolas , Hruban Ralph H. , Maitra Anirban , Wood Laura D.
Published: April 2023

Supplementary Table 3. Somatic mutations in targeted sequencing from Validation Set
Supplemental Table Legends from Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis
Authors: Dal Molin Marco , Zhang Ming , de Wilde Roeland F. , Ottenhof Niki A. , Rezaee Neda , Wolfgang Christopher L. , Blackford Amanda , Vogelstein Bert , Kinzler Kenneth W. , Papadopoulos Nickolas , Hruban Ralph H. , Maitra Anirban , Wood Laura D.
Published: April 2023

Supplemental Table Legends
Supplementary text from A Promyelocytic Leukemia Protein–Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma
Authors: Dvorkina Maria , Nieddu Valentina , Chakelam Shalini , Pezzolo Annalisa , Cantilena Sandra , Leite Ana Paula , Chayka Olesya , Regad Tarik , Pistorio Angela , Sementa Angela Rita , Virasami Alex , Barton Jack , Montano Ximena , Lechertier Tanguy , Brindle Nicola , Morgenstern Daniel , Lebras Morgane , Burns Alan J. , Saunders Nigel J. , Hodivala-Dilke Kairbaan , Bagella Luigi , De The Hugues , Anderson John , Sebire Neil , Pistoia Vito , Sala Arturo , Salomoni Paolo
Published: April 2023

Supplementary legends
Supplementary table 4 from A Promyelocytic Leukemia Protein–Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma
Authors: Dvorkina Maria , Nieddu Valentina , Chakelam Shalini , Pezzolo Annalisa , Cantilena Sandra , Leite Ana Paula , Chayka Olesya , Regad Tarik , Pistorio Angela , Sementa Angela Rita , Virasami Alex , Barton Jack , Montano Ximena , Lechertier Tanguy , Brindle Nicola , Morgenstern Daniel , Lebras Morgane , Burns Alan J. , Saunders Nigel J. , Hodivala-Dilke Kairbaan , Bagella Luigi , De The Hugues , Anderson John , Sebire Neil , Pistoia Vito , Sala Arturo , Salomoni Paolo
Published: April 2023

Microarray data analysis
Supplemental Figure S3 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients
Authors: Guo Yuna , Kenney S. Ray , Cook Linda , Adams Sarah F. , Rutledge Teresa , Romero Elsa , Oprea Tudor I. , Sklar Larry A. , Bedrick Edward , Wiggins Charles L. , Kang Huining , Lomo Lesley , Muller Carolyn Y. , Wandinger-Ness Angela , Hudson Laurie G.
Published: April 2023

Supplemental Figure S3. Racemic distribution of clinical drug.
Supplemental Figure S2 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients
Authors: Guo Yuna , Kenney S. Ray , Cook Linda , Adams Sarah F. , Rutledge Teresa , Romero Elsa , Oprea Tudor I. , Sklar Larry A. , Bedrick Edward , Wiggins Charles L. , Kang Huining , Lomo Lesley , Muller Carolyn Y. , Wandinger-Ness Angela , Hudson Laurie G.
Published: April 2023

Supplemental Figure S2. Purified Ovarian Tumor Cells Express EpCam and MUC16/CA125.
Supplemental Figure S1 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients
Authors: Guo Yuna , Kenney S. Ray , Cook Linda , Adams Sarah F. , Rutledge Teresa , Romero Elsa , Oprea Tudor I. , Sklar Larry A. , Bedrick Edward , Wiggins Charles L. , Kang Huining , Lomo Lesley , Muller Carolyn Y. , Wandinger-Ness Angela , Hudson Laurie G.
Published: April 2023

Supplemental Figure S1. Expression of Rho-family GTPases in primary patient cDNA samples analyzed by grade for serous cancer only.
Supplementary Table 1 from A Promyelocytic Leukemia Protein–Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma
Authors: Dvorkina Maria , Nieddu Valentina , Chakelam Shalini , Pezzolo Annalisa , Cantilena Sandra , Leite Ana Paula , Chayka Olesya , Regad Tarik , Pistorio Angela , Sementa Angela Rita , Virasami Alex , Barton Jack , Montano Ximena , Lechertier Tanguy , Brindle Nicola , Morgenstern Daniel , Lebras Morgane , Burns Alan J. , Saunders Nigel J. , Hodivala-Dilke Kairbaan , Bagella Luigi , De The Hugues , Anderson John , Sebire Neil , Pistoia Vito , Sala Arturo , Salomoni Paolo
Published: April 2023

Correlation of PML expression with tumor relapse/outcome in localised and metastatic tumours (Gaslini and first ICH/GOSH cohort)
Supplementary Table Legend from A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
Authors: Kaye Stanley B. , Fehrenbacher Louis , Holloway Robert , Amit Amnon , Karlan Beth , Slomovitz Brian , Sabbatini Paul , Fu Ling , Yauch Robert L. , Chang Ilsung , Reddy Josina C.
Published: April 2023

PDF file - 44K
Supplementary Table 1 from A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
Authors: Kaye Stanley B. , Fehrenbacher Louis , Holloway Robert , Amit Amnon , Karlan Beth , Slomovitz Brian , Sabbatini Paul , Fu Ling , Yauch Robert L. , Chang Ilsung , Reddy Josina C.
Published: April 2023

PDF file - 61K, Primer/probes used for qRT-PCR profiling of Hedgehog (Hh) pathway genes. A table highlighting the primers and probes used for qRT-PCR profiling.
Supplementary Figure 1 from A Promyelocytic Leukemia Protein–Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma
Authors: Dvorkina Maria , Nieddu Valentina , Chakelam Shalini , Pezzolo Annalisa , Cantilena Sandra , Leite Ana Paula , Chayka Olesya , Regad Tarik , Pistorio Angela , Sementa Angela Rita , Virasami Alex , Barton Jack , Montano Ximena , Lechertier Tanguy , Brindle Nicola , Morgenstern Daniel , Lebras Morgane , Burns Alan J. , Saunders Nigel J. , Hodivala-Dilke Kairbaan , Bagella Luigi , De The Hugues , Anderson John , Sebire Neil , Pistoia Vito , Sala Arturo , Salomoni Paolo
Published: April 2023

MYCN and PML correlation
Related Article from Molecular Precision Chemotherapy: Overcoming Resistance to Targeted Therapies?
Authors: Burdach Stefan
Published: April 2023

Related Article from Molecular Precision Chemotherapy: Overcoming Resistance to Targeted Therapies?
Data Supplement from Systematically Defining Single-Gene Determinants of Response to Neoadjuvant Chemotherapy Reveals Specific Biomarkers
Authors: Witkiewicz Agnieszka K. , Balaji Uthra , Knudsen Erik S.
Published: April 2023

Supplemental Figure Legend
Supplemental Tables 1 and 2 from Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer
Authors: Zhang Liang , Wang Xiaoen , Bullock Andrea J. , Callea Marcella , Shah Harleen , Song Jiaxi , Moreno Kelli , Visentin Barbara , Deutschman Douglas , Alsop David C. , Atkins Michael B. , Mier James W. , Signoretti Sabina , Bhasin Manoj , Sabbadini Roger A. , Bhatt Rupal S.
Published: April 2023

Table S1: Plasma S1P levels in patients with RCC; Table S2: Table of ASL MRI values.
Supplementary Table S2 from Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer
Authors: Koido Shigeo , Homma Sadamu , Okamoto Masato , Takakura Kazuki , Mori Masako , Yoshizaki Shinji , Tsukinaga Shintaro , Odahara Shunichi , Koyama Seita , Imazu Hiroo , Uchiyama Kan , Kajihara Mikio , Arakawa Hiroshi , Misawa Takeyuki , Toyama Yoichi , Yanagisawa Satoru , Ikegami Masahiro , Kan Shin , Hayashi Kazumi , Komita Hideo , Kamata Yuko , Ito Masaki , Ishidao Takefumi , Yusa Sei-ichi , Shimodaira Shigetaka , Gong Jianlin , Sugiyama Haruo , Ohkusa Toshifumi , Tajiri Hisao
Published: April 2023

Clinical efficacy results of patients with pancreatic ductal adenocarcinoma.
Supplemental Table 5 from First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Authors: Shapiro Geoffrey I. , Bell-McGuinn Katherine M. , Molina Julian R. , Bendell Johanna , Spicer James , Kwak Eunice L. , Pandya Susan S. , Millham Robert , Borzillo Gary , Pierce Kristen J. , Han Lixin , Houk Brett E. , Gallo Jorge D. , Alsina Maria , Braña Irene , Tabernero Josep
Published: April 2023

Supplemental Table 5. presents a summary of the responses and clinical benefit observed in patients with advanced solid malignancies following treatment with PF-05212384.
Supplementary Figure Legend from Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer
Authors: Koido Shigeo , Homma Sadamu , Okamoto Masato , Takakura Kazuki , Mori Masako , Yoshizaki Shinji , Tsukinaga Shintaro , Odahara Shunichi , Koyama Seita , Imazu Hiroo , Uchiyama Kan , Kajihara Mikio , Arakawa Hiroshi , Misawa Takeyuki , Toyama Yoichi , Yanagisawa Satoru , Ikegami Masahiro , Kan Shin , Hayashi Kazumi , Komita Hideo , Kamata Yuko , Ito Masaki , Ishidao Takefumi , Yusa Sei-ichi , Shimodaira Shigetaka , Gong Jianlin , Sugiyama Haruo , Ohkusa Toshifumi , Tajiri Hisao
Published: April 2023

Supplementary Figure Legend from Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer
Supplementary Figures 1 - 4 from A High-Affinity, High-Stability Photoacoustic Agent for Imaging Gastrin-Releasing Peptide Receptor in Prostate Cancer
Authors: Levi Jelena , Sathirachinda Ataya , Gambhir Sanjiv S.
Published: April 2023

PDF file - 300KB, Contains information about the dyes tested and characterization of the imaging agents. Figure S1. Dye Selection. The table lists all the dyes tested with their molecular weight, maximum excitation and emission wavelengths, extinction coefficient and quantum yield. Figure S2. AA3G-740 MALDI spectrum. Figure S3. Cell binding studies. A) Binding of AA3G-740 to PC3 cells was blocked by bombesin in a dose dependent manner. B) LNCaP cells showed minimal binding. At high concentration (30pmol) cell fluorescence was of a similar level as the one corresponding to non-specific binding in PC3 cells Figure S4. Blood lifetime. Very low amount of the agent was at 60 minutes post-injection suggesting short blood lifetime.
Supplementary Tables 16 - 22 from Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Authors: Cui Yunfeng , Brosnan Jacqueline A. , Blackford Amanda L. , Sur Surojit , Hruban Ralph H. , Kinzler Kenneth W. , Vogelstein Bert , Maitra Anirban , Diaz Luis A. , Iacobuzio-Donahue Christine A. , Eshleman James R.
Published: April 2023

PDF file, 175K, S16 Genes with significant different gene expression in cell cycle, apoptosis, autophagy, DNA repair, tumor suppressor gene and anticancer drug metabolism pathway between sensitive and resistant human pancreatic cancer cells; S17 Chemosensitive differences of anticancer drugs between familial and sporadic pancreatic cancer cell lines; S18 Sensitivity-related gene sets for each drug by employing Gene set enrichment analysis for sensitive versus resistant cell lines; S19 Genes with significant different gene expression in cell cycle, apoptosis, autophagy, DNA repair, tumor suppressor gene and anticancer drug metabolism pathway between DPC4.md and DPC4.wt human pancreatic cancer cells; S20 Genes with significant different gene expression in cell cycle, apoptosis, autophagy, DNA repair, tumor suppressor gene and anticancer drug metabolism pathway between TP53.md and TP53.wt human pancreatic cancer cells; S21 Genes with significant different gene expression in cell cycle, apoptosis, autophagy, DNA repair, tumor suppressor gene and anticancer drug metabolism pathway between P16.md and P16.wt human pancreatic cancer cells; S22 Genes with significant different gene expression in PC cells clustering in a triangle network.
Supplementary Figure 2 from Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model
Authors: Sun Zhi-Jun , Zhang Lu , Hall Bradford , Bian Yansong , Gutkind J. Silvio , Kulkarni Ashok B.
Published: April 2023

PDF file - 929K, Increased levels of p-Akt, p-S6 and survivin in Tgfbr1/Pten 2cKO HNSCC as compared to Pten cKO HNSCC
Supplementary Figure 2 from LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma
Authors: Yeung Jacky T. , Hamilton Ronald L. , Ohnishi Koji , Ikeura Maki , Potter Douglas M. , Nikiforova Marina N. , Ferrone Soldano , Jakacki Regina I. , Pollack Ian F. , Okada Hideho
Published: April 2023

PDF file - 439K, Additional representative images of HLA Class I and CD8 immunohistochemistry.
EMT supplementary figures from Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
Authors: Lou Yanyan , Diao Lixia , Cuentas Edwin Roger Parra , Denning Warren L. , Chen Limo , Fan You Hong , Byers Lauren A. , Wang Jing , Papadimitrakopoulou Vassiliki A. , Behrens Carmen , Rodriguez Jaime Canales , Hwu Patrick , Wistuba Ignacio I. , Heymach John V. , Gibbons Don L.
Published: April 2023

Supplementary Table 1. Patient demographic and clinical characteristics. Supplementary Table 2. Immune-related gene list. Immune related molecules demonstrating roles in tumor microenvironment based on publications were listed in the table and used in this study. Supplementary Table 3. Common mutational events in "epithelial" and "mesenchymal" lung adenocarcinomas versus EMT status. Supplementary Figure 1. Validation of anti-PD-L1 antibody E1L3N (Cell Signaling Technology). Supplementary Figure 2. Validation of anti-PD-L1 antibody ab174838 (Abcam). Supplementary Figure 3. Elevation of multiple immune molecules in "mesenchymal" compared to "epithelial" lung adenocarcinoma. Supplementary Figure 4. B7-H3 is associated with poor OS and RFS in lung adenocarcinoma. Supplementary Figure 5. The association between EMT and inflammatory tumor microenvironment in advanced lung adenocarcinoma.